Pages that link to "Q34167551"

The following pages link to Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings. (Q34167551):

Displaying 20 items.

• Neural substrates of cue reactivity: association with treatment outcomes and relapse (Q26782278) (← links)
• The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study. (Q27310644) (← links)
• Severity of alcohol dependence is negatively related to hypothalamic and prefrontal cortical gray matter density in heavy drinking smokers (Q33806365) (← links)
• Differences in quit attempts between non-Hispanic Black and White daily smokers: the role of smoking motives (Q35060876) (← links)
• Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings. (Q35195302) (← links)
• Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers. (Q35689017) (← links)
• Nicotinic Mechanisms Modulate Ethanol Withdrawal and Modify Time Course and Symptoms Severity of Simultaneous Withdrawal from Alcohol and Nicotine (Q35960331) (← links)
• Pharmacological Options for Smoking Cessation in Heavy-Drinking Smokers (Q36294656) (← links)
• Current insights into the mechanisms and development of treatments for heavy drinking cigarette smokers (Q36877440) (← links)
• Tobacco Cessation Interventions for Underserved Women (Q36903644) (← links)
• Endogenous opioid system: a promising target for future smoking cessation medications (Q38747115) (← links)
• Relationship between negative affect and smoking topography in heavy drinking smokers (Q38860859) (← links)
• Combining Varenicline (Chantix) with Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in a Rodent Model of Alcoholism. (Q42149212) (← links)
• Co-Administration of Low-Dose Naltrexone and Bupropion Reduces Alcohol Drinking in Alcohol-Preferring (P) Rats. (Q48148853) (← links)
• Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users: A Preliminary Laboratory Study (Q50042559) (← links)
• A Combination of Naltrexone   Varenicline Retards the Expression of a Genetic Predisposition Toward High Alcohol Drinking. (Q54998102) (← links)
• A Brief Smoking Cessation Intervention for Heavy Drinking Smokers: Treatment Feasibility and Acceptability (Q58790176) (← links)
• Distress Tolerance and Craving for Cigarettes Among Heavy Drinking Smokers (Q90677146) (← links)
• Building better strategies to develop new medications in Alcohol Use Disorder: Learning from past success and failure to shape a brighter future (Q92189687) (← links)
• Mechanisms and Clinical Features of Co-occurring Opioid and Nicotine Use (Q99630771) (← links)